Syndicated Post-SABCS 2014 OncoPoll™: Global Breast Cancer Disease Landscape

Introduction

In an effort to provide you with timely market feedback from SABCS 2014, OBR and MDoutlook^® are pleased to share results from MDoutlook’s OncoPoll from the meeting. This report explored the impact of new data presented at SABCS 2014.

OncoPoll™ Methodology

• Primary research phase involved a global survey to MDoutlook’s panel of verified and validated medical oncologists screened for patient volume in breast cancer
• Timing: December 2014. Launched three days after close of SABCS 2014, held in San Antonio, Texas December 9 – 13, 2014

• Reponses at data collection: 125 respondents representing 15 countries
  • 41 US respondents
  • 15 German respondents
  • 14 French respondents
  • 15 Italian respondents
  • 15 Spanish respondents
  • 25 Rest of Europe (ROE) respondents

Attendance at SABCS 2014

Key Conclusions

• Nearly a 50/50 split of Italian, Spanish, and ROE respondents attended the SABCS 2014
• The majority of US survey respondents attended SABCS 2014

Survey Participants’ Breast Cancer Patient Flow: Average Over 20 Early and Metastatic Breast Cancer Cases Each Quarter

Key Conclusion

• The largest proportion of mBRCA patients treated by respondents are HER2- HR2+ (30-60%)

Assessment of New Agents in Breast Cancer Pipeline: Cumulatively, Physicians Assess New Agents Pembrolizumab and MPDL3280A to Potentially Have Largest Clinical Impact on Breast Cancer Patients

Key Conclusions

• Of the 13 new agents listed, pembrolizumab (anti-PD-1 mAb; S1-09) (35%) and MPDL3280A (anti-PD-1L; PD1-6) (31%) have the highest proportion of physicians who project they will have a “large impact for many patients”
• However, for each new agent listed, the highest proportion of physicians project they will have a “large impact for few patients”
• All new agents also have 2%-15% of physicians who project they will have “little to no value”

Adjuvant Therapy

NSABP B-36 Trial (Phase 3)

Clinical Impact NSABP B-36 Trial on Adjuvant Therapy: Usage of 4 Cycles of AC Projected To Grow (Except U.S.) – Usage of 6 Cycles of FEC Projected to Decrease (Except U.S.)

Key Conclusions

• Unlike in Europe, U.S. physicians project to increase usage of 6 cycles of FEC (11% to 20% of patients) and slightly decrease (44% to 43% of patients) usage of 4 cycles of AC adjuvant therapy for node-negative breast cancer patients
• Overall, European physicians plan to decrease the usage of 6 cycles of FEC and increase the usage of 4 cycles of AC as adjuvant therapy

Supportive Care

Febrile Neutropenia (FN) In Breast Cancer: Approximately 1 in 8 Breast Cancer Patients Develop Febrile Neutropenia

Key Conclusions

• U.S. and ROE physicians report on average 15% of their patients develop FN
• All other countries report 9% – 12% of their patients develop FN

Current Treatment for FN

Key Conclusions

• U.S. is only country where pegfilgrastim is used on more patients (50%) then filgrastim (44%) as a treatment for FN
• In all other countries, filgrastim is used on more patients at approximately 60% / 40% split.
• Very few patients are receiving other treatments for FN. Other treatments include:
  • Leukine (US), Granix (US), and ROE physicians indicated “no primary GCSF prophylaxis”

Respondents Overwhelmingly Expect to Prescribe Biosimilar GCSF if Approved by FDA

Key Conclusions

• 90+% of German and Italian respondents and ~80% of US and French physicians project they will prescribe a biosimilar GCSF if approved by FDA
• 60+% of Spanish and ROE physicians expect to prescribe a biosimilar GCSF if approved
• Physicians saying no: U.S. (9%), ROE (25%), Spain (20%) and Italy (8%)